Abstract
Background The RYR1 gene codes for a ryanodine receptor which is a calcium release channel in the skeletal muscle sarcoplasmic reticulum. It is associated with Malignant Hyperthermia (MH) and several congenital myopathies including Central Core Disease (CCD), Multiminicore Disease (MMD) and Congenital Fibre-Type Disproportion (CFTD). There is currently little information on the epidemiology of RYR1 variants in Asians. Our study aims to describe the RYR1 variant landscape in a Singapore cohort unselected for RYR1-associated conditions.
Methods Data was retrieved from the SG10K pilot project, where whole genome sequencing was performed on volunteers unselected and undetermined for RYR1-associated conditions. Variants were classified based on pathogenicity using databases ClinVar and InterVar. Allele frequencies of pathogenic variants were compared between Chinese, Indians and Malays. Using databases ExAC, GnomAD and GenomeAsia 100k study, we further compared local allele frequencies to those in Europe, America and Asia.
Results Majority of the RYR1 variants were missense mutations. We identified four pathogenic and four likely pathogenic RYR1 variants. All were related to the aforementioned RYR1-associated conditions. There were 6 carriers of RYR1 pathogenic variants amongst 4810 individuals, corresponding to an allele frequency of 0.06%. The prevalence of pathogenic variants was the highest amongst Indians (4 in 1127 individuals). Majority of pathogenic and likely pathogenic mutations were missense and located in mutational hotspots. These variants also occurred at higher frequencies in Asians than globally.
Conclusion This study describes the variant landscape of the RYR1 gene in Singapore. This knowledge will facilitate local efforts in developing precision medicine.
Competing Interest Statement
A.I. is an employee of Nalagenetics Pte Ltd. A.I. and J.L. has financial holdings in Nalagenetics Pte Ltd.
Funding Statement
Support was provided by the Department of Anaesthesia, National University Health System Singapore.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These studies were approved by the Institutional Review Board of the National University of Singapore (Approvals: N-17-030E and H-17-049), SingHealth Centralized Institutional Review Board (Approvals: 2006/612/A, 2014/160/A, 2018/2570, 2018/2717, 2010/196/C, 2015/2194, 2019/2046, 2009/280/D, 2014/692/D, 2002/008/A, 2002/008 g/A, 2013/605/C, 2018/3081 and 2015/2308), National Health Group Domain Specific Review Board (Approvals: 2007/00167, 2016/00269, 2018/00301, TTSH/2014-00040 and 2009/00021).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The accession number for the sequence data reported in this paper is EGA: EGAS00001003875.
Abbreviations
- MH
- malignant hyperthermia
- SNV
- single nucleotide variants